MIRM
Mirum Pharmaceuticals, Inc.
$120.89
+1.85 (+1.55%)
At close · Jul 14
Market Cap
$7.32B
Shares
60,981,227
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$521.31M
+54.7%
FY2025
Net Income
-$23.36M
+73.4%
FY2025
Operating Margin
-4.25%
+21.8pp
FY2025
Diluted EPS
-$0.47
+74.6%
FY2025
Operating Cash Flow
$55.83M
+440.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $660M – $680M | $569.61M | $521.31MG | $336.89M | $186.37M | $77.06M | $19.14M | $0 | — | |
| — | $243.04M | $186.18M | $140.63M | $102.61M | $106.84M | $131.43M | $81.61M | $42.99M | |
| — | — | — | — | — | — | $59.22M | $22.69M | $11.75M | |
| — | $295.65M | $257.03M | $202.22M | $145.88M | $89.07M | $59.22M | — | — | |
| — | $24.7M | $23.9M | $23.1M | $10.5M | $2.9M | $300K | — | — | |
| — | — | $24.24M | $23.63M | $10.83M | $3.24M | $595K | $305K | $139K | |
| — | $1.37B | $543.45M | $424.49M | $295.53M | $208.28M | $192.55M | $104.3M | $54.74M | |
| — | -$796.42M | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M | -$104.3M | -$54.74M | |
| — | — | -4.25% | -26% | -58.57% | -170.28% | -906.12% | — | — | |
| — | — | $2.11M | -$63.98M | -$98.33M | -$127.98M | -$172.82M | -$103.99M | -$54.6M | |
| — | $14.41M | $14.39M | $14.31M | $15.11M | $15.98M | — | — | — | |
| — | $13.11M | $12.73M | $13.79M | $13.74M | $3.86M | $366K | $1.56M | $2.23M | |
| — | $263K | $2.37M | $1.21M | -$2.82M | $365K | -$582K | -$192K | -$21K | |
| — | -$797.46M | -$21.43M | -$86.91M | -$162.42M | -$142.07M | -$83.95M | -$103.26M | -$52.53M | |
| — | $1.38M | $1.94M | $1.03M | $991K | -$6.41M | $37K | $6000 | $21K | |
| — | -$798.84M | -$23.36M | -$87.94M | -$163.42M | -$135.67M | -$83.99M | -$103.27M | -$52.55M | |
| — | — | -4.48% | -26.1% | -87.68% | -176.05% | -438.85% | — | — | |
| — | — | — | -$87.94M | -$163.42M | -$135.67M | -$83.99M | — | — | |
| — | -$798.61M | -$22.64M | -$89.96M | -$161.55M | -$135.85M | -$84.11M | -$103.32M | -$52.42M | |
| USD/shares | — | — | -$0.47 | -$1.85 | -$4.00 | -$4.01 | -$2.77 | — | — |
| USD/shares | — | — | -$0.47 | -$1.85 | -$4.00 | -$4.02 | -$2.77 | — | — |
| shares | — | — | 50.2M | 47.52M | 40.89M | 33.84M | 30.32M | 25.25M | 11.49M |
| shares | — | — | 50.2M | 47.52M | 40.89M | 33.98M | 30.32M | 25.25M | 11.49M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $521,312,000 | $336,888,000 | $186,374,000 | $77,062,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Product | $521,312,000 | $336,409,000 | $178,874,000 | $75,062,000 | $3,138,000 | $0 |
| Livmarli | $360,006,000 | $213,295,000 | $141,795,000 | $75,062,000 | $3,138,000 | — |
| Bile Acid Medicines | $161,306,000 | $123,114,000 | $37,079,000 | $0 | $0 | — |
| License and Other Revenue | $0 | $479,000 | $7,500,000 | $2,000,000 | — | — |
| License Revenue | — | — | $7,500,000 | $2,000,000 | $16,000,000 | — |
| License | — | — | $7,500,000 | $2,000,000 | $16,000,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | -$22,136,000 | -$87,606,000 | -$109,154,000 | -$131,220,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | -4.2% | -26% | -58.6% | -170.3% |
Key facts
CIK
1759425
CUSIP
604749101
13F (30d)
14 filings
13 filers
Visit website
Investor relations